Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs
By Ivan Moreno · August 5, 2026, 3:14 PM EDT
A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight-loss drugs that...
To view the full article, register now.